Afer an overnight fast a double lumen gastric tube was positioned in the antral part of the stomach under fluoroscopic control. Phenol red (0.1%), a non-absorbable marker, was used to correct for duodenal volume loss11 and instilled into the stomach close to the cardia at a flow rate of 200 ml/h.
In a follow up study the same volunteers received 200 gg of SMS subcutaneously. The same experimental protocol was used as described before.
DETERMINATIONS
The volume of all aspirates was measured and the gastric juice analysed for the concentration of H+ and phenol red. Acid concentration was estimated by titration with 0 01 mol sodium hydroxide to an end point of pH 7-0 using an electrometric autotitrator (Methrom, Herisau, Switzerland). Phenol red concentration was determined by photometry at 546 nm wave length.
Somatostatin concentration in non-extracted plasma was determined by a sensitive and specific radioimmunoassay. Briefly, the antiserum originated from a mouse which had been immunised with the peptide conjugated to haemocyanin. As a tracer, the (Tyr1)-analogue of SMS was iodinated and purified on HPLC. Detection was limited to 0.02 ng/ml plasma. All samples were assayed in duplicate. 13 Pentagastrin ( Table. In our study no significant decrease of acid concentration and of acid secretion was observed over the six hours of the placebo administration, although both parameters had a tendency to decline towards the end of the experiment (Fig. 1) .
A single subcutaneous injection of SMS (100 ,ug) decreased pentagastrin stimulated acid secretion within 15 minutes after administration. The time course and extent of inhibition of gastric acid output are given in Figure 1 . Somatostatin inhibited gastric acid secretion throughout the five hour observation , Table) .
Comparison of gastric fluid secretion during the control period shows no significant difference in the three experiments (Table) . Tota fluid secretion per five hours was significantly suppressed by somatostatin compared with placebo administration (p<005 , Table) (Table) .
The time course of plasma somatostatin is given in Figure 3 . Immunoreactive somatostatin increased rapidly after subcutaneous injection of 100 ,ug reaching a mean peak concentration of 3.5±0-5 ng/ml after 14-0±4-5 min. After five hours, plasma somatostatin concentrations had decreased to 0*4±0-1 ng/ml. The respective results for the 200 ,ug dose were: peak concentration=11-5±1-4 ng/ml after 20-8±4-6 min; plasma somatostatin concentrations after five hours: 1 17 The clinical value of SMS has, however, been limited owing to its very short duration of action and by its lack of specificity of its effects2 5 15 and by considerable costs.4
Synthetic SMS would appear to have overcome the first of these problems, but still retained the inhibitory activity of its mother peptide. Maximal pentagastrin stimulated acid secretion was effectively and equally suppressed for five hours after a single subcutaneous injection. This was quite unexpected, as in pilot experiments SMS has been estimated to have a plasma half life of around 90 minutes after subcutaneous injection. The data of the above study confirm that the half life of SMS after subcutaneous injection of 100 ,ug is around 80 minutes. The discrepancy between plasma half life and biological effect is an interesting observation and suggests that plasma concentrations alone cannot be used to monitor the efficacy of the peptide. The plasma data clearly show that the prolonged action of the subcutaneous injection is not because of the slow uptake from the site of injection, but must be related to a direct effect on the SMS receptor.
In an attempt to further characterise the efficacy of SMS, we administered 200 ,ug of the peptide to the same volunteers in a follow up study. No further inhibition of acid secretion was observed with this dose, despite plasma SMS concentrations which were three times higher than with the lower dose.
SMS (1009)or plocebo
Therefore, 100 ,ug of SMS seem to be a maximal effective subcutaneous dose for suppressing gastric acid secretion. Half life was found to be very similar after both doses and interpatient variability was very low. Therefore nothing will be gained, with regard to acid secretion, by doubling the dose of the peptide.
An interesting observation in these studies is the lack of a significant decrease of acid secretion after a near maximal dose of pentagastrin administered over six hours in the placebo experiments. This suggests that the stomach is capable of secreting near maximal rates for several hours confirming and extending the observations of a recent Scandinavian study in which gastric acid secretion was well maintained for four hours during intravenous penta- (Table) , confirming our previous results with natural somatostatin.10 22 It therefore appears that the inhibitory effects of somatostatin peptides is primarily on the quantity of acid secreted and not on the volume.
The ability of the somatostatin analogue to suppress near maximal gastric acid secretion for several hours after subcutaneous injection might render the peptide useful in patients with bleeding peptic ulcers or with peptic ulcer disease not requiring intravenous treatment. None of our volunteers experienced any untoward symptoms at the dose of somatostatin used in the present study. Further studies of the therapeutic potential of this peptide are clearly indicated.
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